DIA/FDA Oligonucleotide-Based Therapeutics Conference

Join us at the FDA / DIA Oligonucleotide-Based Therapeutics Conference brings together leading experts to inform, educate, and share
advancements in oligonucleotide-based therapeutic product development. Developed collaboratively by regulators, industry
professionals, and academics, the program covers a wide range of topics from the nonclinical, CMC, and clinical areas,
including emerging CMC guidances and considerations, learnings from recent regulatory filings, extra-hepatic and CNS delivery
of oligonucleotides, toxicology testing, gene editing, and safety assessments. The conference offers a unique three-day
experience with multiple perspectives presented, and the opportunity to interface with regulators from around the globe